A disruptive technology for vaccines manufacturing based on Self-Assembled Polymeric Nanoparticulate systems

Projektinformationen

SAP-Nano

ID Finanzhilfevereinbarung: 728455

DOI

10.3030/728455

Projekt abgeschlossen

EK-Unterschriftsdatum 21 Mai 2016

Startdatum 1 Juni 2016

Enddatum 30 November 2016

Finanziert unter

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies

Gesamtkosten

€ 71 429,00

EU-Beitrag

€ 50 000,00

Koordiniert durch

BIONANOPLUS SL
Spain

Periodic Reporting for period 1 - SAP-Nano (A disruptive technology for vaccines manufacturing based on Self-Assembled Polymeric Nanoparticulate systems)

Berichtszeitraum: 2016-06-01 bis 2016-11-30

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

The SAP-Nano project by Bionanoplus S.L. was approved within the call for SME Instrument H2020, Topic NMP-25-2015: Accelerating the uptake of nanotechnologies, advanced materials or advanced manufacturing and processing technologies by SMEs, Call 2016-02-24.
Bionanoplus detected the major problems faced by many pharmaceutical, veterinary and cosmetic sector manufacturers to develop products using nanotechnology.
Bionanoplus has solved the scalability problem of traditional nanoparticle manufacturing methods avoiding the use of volatile organic solvents, thus it ensures an easy and inexpensive production of any scale, which can be performed using standard equipment and techniques.
SAP-Nano technology allows vaccine manufacturers to produce very effective vaccines without using the traditional adjuvants, avoiding the side effects these have.
On the other hand, PRRSV is the major cause of reproductive and respiratory problems in pigs worldwide. It is endemic in Europe and other parts of the world. It was estimated that losses due to PRRSV cost the swine industry EUR 1.5 billion per year in Europe and USD 664 million per year in the USA.
Bionanoplus has chosen firstly the PRRSV vaccines market due to the combination of it being a big market with a clear need to solve a problem and the capacity of the company to cover these needs with SAP-Nano technology.
The general objective of the Project was to test the economic feasibility of this new vaccination technology in an interesting industry (swine producers) and to prepare the launch of this technology on to the market.
The Project has been developed as planned, in terms of deadlines, budgets, actions, and results obtained.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

Thanks to the market research, Bionanoplus have found a partner to guarantee and validate the source of antigen supply for the production of the vaccines. This partner will collaborate with Bionanoplus in the final development and commercialization of the SAP-Nano PRRSV vaccine. We have also design a thoroughly strategy to approach potential clients, preparing the commercial and marketing material to address the international market. We have established the road map to commercialisation. Finally, the business model has been designed employing the Canvas methodology, along with the alliance, and business and marketing strategies. The company has undertaken a very important strategic reflection, involving the whole organization. As a result, we have development of a comprehensive business plan, which includes an economic & financial plan for the next four years

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

With its breakthrough technology Bionanoplus will contribute to improving the competitiveness of the vaccine manufacturer sector in Europe.
Apart from improving animal health and productivity, veterinary vaccines have a significant impact on public health through reductions in the use of veterinary pharmaceuticals and hormones and their residues in the human food chain.
The Project will generate qualified job positions at Bionanoplus as well as positions at European vaccine manufacturers.
Promoters expects to demonstrate that Bionanoplus will be soon an internationally recognized company within the field of polymeric nanoencapsulation solutions to develop innovative vaccines.

Bionanoplus Logo